Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America . Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-ॅ-2b (PegIFN-ॅ-2b) or -ॅ-2a (PegIFN-ॅ-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority. Here we report that a genetic polymorphism near the IL28B gene, encoding interferon-ॕ-3 (IFN-ॕ-3), is associated with an approximately twofold change in response to treatment, both among patients of European ancestry ( P = 1.06 × 10 -25 ) and African-Americans ( P = 2.06 × 10 -3 ). Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Nature Publishing Group (NPG)

Loading next page...
 
/lp/nature-publishing-group-npg/genetic-variation-in-il28b-predicts-hepatitis-c-treatment-induced-ACwWYnIXSg
Publisher
Nature Publishing Group (NPG)
Copyright
Copyright © 2009 Macmillan Publishers Limited. All rights reserved
ISSN
0028-0836
eISSN
1476-4687
D.O.I.
10.1038/nature08309
Publisher site
See Article on Publisher Site

Abstract

Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America . Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-ॅ-2b (PegIFN-ॅ-2b) or -ॅ-2a (PegIFN-ॅ-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority. Here we report that a genetic polymorphism near the IL28B gene, encoding interferon-ॕ-3 (IFN-ॕ-3), is associated with an approximately twofold change in response to treatment, both among patients of European ancestry ( P = 1.06 × 10 -25 ) and African-Americans ( P = 2.06 × 10 -3 ). Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry.

Journal

NatureNature Publishing Group (NPG)

Published: Aug 16, 2009

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off